Radiation oncology firm Elekta has decided not to bid on a linear accelerator contract proposed by the Ministry of Health in Brazil.
The price for 80 linear accelerators, a customer service and support package, project management, software, and brachytherapy equipment, with tax, had declined to less than $55 million, to which Elekta could not commit.
In a prepared statement, Elekta President and CEO Tomas Puusepp said Brazil continues to be a "growth market" for the company, but the price declined to "unsustainable levels."
"Elekta does not consider it possible to deliver the right quality and support to our Brazilian customer base at that price level," he added.
